Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 27, Number 1—January 2021
Letter

Relative Bradycardia in Patients with Mild-to-Moderate Coronavirus Disease, Japan

Suggested citation for this article

To the Editors: Ikeuchi et al. (1) described the phenomenon of relative bradycardia in patients as an adjunct to the clinical diagnosis of mild-to-moderate coronavirus disease (COVID-19). Relative bradycardia is defined as an increase in pulse rate of <18 bpm for each 1°C rise in body temperature or a body temperature >38.9°C and pulse rate <120 bpm (2). We performed a retrospective study comparing COVID-19 and influenza patients in a tertiary hospital in Singapore. Our study was reviewed and approved by the National Healthcare Group Domain Specific Review Board (reference no. 2020/00324)

We reviewed medical records of patients with COVID-19 or influenza, confirmed by reverse transcription PCR, who were treated during October 2019–April 2020. Patients on β-blockers were excluded (14 COVID-19 patients and 25 influenza patients). Eighty-six patients with COVID-19 and 74 patients with influenza were included; 73 influenza cases were influenza A and 1 influenza B. For COVID-19 patients, median age was 40.6 (range 18–72) years and 49/86 (57%) were male; for influenza patients, median age was 54 (range 22–85) years and 34/74 (45.9%) were male. Fourteen (16.3%) COVID-19 patients and 29 (39.2%) influenza patients had fever >38.9°C; only 4 (13.8%) influenza patients and 0 COVID-19 patients had pulse rates >120 bpm. Median pulse rate was 98.5 (interquartile range 94–101) bpm for COVID-19 patients and 99 (interquartile range 97–116) bpm for influenza patients. Linear regression of the peak temperature and the associated pulse rate of the patient predicted an increase in pulse rate of 11.12 (95% CI 7.65–14.60) bpm for COVID-19 patients and 9.5 (95% CI 5.86–13.14) bpm for influenza patients for each 1°C increase in body temperature.

Our data support the observations by Ikeuchi et al. (1) of relative bradycardia in COVID-19 patients. However, results from our cohort demonstrate relative bradycardia in patients with both viral illnesses, indicating that this phenomenon cannot be used to reliably distinguish COVID-19 from influenza and has limited clinical utility in patients who have acute respiratory illnesses.

Top

Gabriel Yan1Comments to Author , Alicia Ang, Sai Meng Tham, Alvin Ng, and Ka Lip Chew1

Author affiliation: National University Health System, Singapore

Top

References

  1. Ikeuchi  K, Saito  M, Yamamoto  S, Nagai  H, Adachi  E. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2020;26:25046. DOIPubMed
  2. Cunha  BA. The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect. 2000;6:6334. DOIPubMed

Top

Suggested citation for this article: Yan G, Ang A, Tham SM, Ng A, Chew KL. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2021 Jan [date cited]. https://doi.org/10.3201/eid2701.203312

DOI: 10.3201/eid2701.203312

1These authors contributed equally to this article.

Related Links

Top

Table of Contents – Volume 27, Number 1—January 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Gabriel Yan, Division of Infectious Diseases, Department of Medicine, National University Health System, NUHS Tower Block, 1E Kent Ridge Rd, Singapore 119228

Send To

10000 character(s) remaining.

Top

Page created: September 29, 2020 6:35 PM EDT
Page updated: November 12, 2020 7:17 PM EST
Page reviewed: November 12, 2020 7:17 PM EST
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external